These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36970763)

  • 1. Real-world cost of care and site of care in patients with multiple sclerosis initiating infused disease-modifying therapies.
    Alvarez E; Nair KV; Tan H; Rathi K; Gabler NB; Maiese EM; Deshpande C; Shao Q
    J Med Econ; 2023; 26(1):494-502. PubMed ID: 36970763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world cost of treatment for multiple sclerosis patients initiating and receiving infused disease-modifying therapies per recommended label in the United States.
    Nicholas J; Halpern R; Ziehn M; Peterson-Brandt J; Leszko M; Deshpande C
    J Med Econ; 2020 Aug; 23(8):885-893. PubMed ID: 32338098
    [No Abstract]   [Full Text] [Related]  

  • 3. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data.
    Engmann NJ; Sheinson D; Bawa K; Ng CD; Pardo G
    J Manag Care Spec Pharm; 2021 May; 27(5):639-649. PubMed ID: 33624535
    [No Abstract]   [Full Text] [Related]  

  • 4. Utilization, cost trends, and member cost-share for self-injectable multiple sclerosis drugs--pharmacy and medical benefit spending from 2004 through 2007.
    Kunze AM; Gunderson BW; Gleason PP; Heaton AH; Johnson SV
    J Manag Care Pharm; 2007; 13(9):799-806. PubMed ID: 18062731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis.
    Kim Y; Krause TM; Blum P; Freeman L
    Mult Scler Relat Disord; 2019 May; 30():69-75. PubMed ID: 30738875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
    Neuberger EE; Abbass IM; Jones E; Engmann NJ
    Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database.
    Prescott JD; Factor S; Pill M; Levi GW
    J Manag Care Pharm; 2007; 13(1):44-52. PubMed ID: 17269836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantifying the administration and monitoring time burden of several disease-modifying therapies for relapsing multiple sclerosis in the United Kingdom: A time and motion study.
    Rog D; Brownlee W; Carod-Artal FJ; Kalra S; Barker N; Lowndes C; Pendlebury J; Leclerc S; Amin A; Ashton L; Evans H; De Cock E
    Mult Scler Relat Disord; 2024 Feb; 82():105380. PubMed ID: 38183696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world experience of ocrelizumab initiation in a diverse multiple sclerosis population.
    Coban H; Germaine S; Dimaandal I; Haberli N; Padam C; Creed MA; Imitola J
    Mult Scler Relat Disord; 2021 Aug; 53():103021. PubMed ID: 34077828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease Evolution in Women With Highly Active MS Who Suspended Natalizumab During Pregnancy vs Rituximab/Ocrelizumab Before Conception.
    Demortiere S; Maarouf A; Rico A; Boutiere C; Hilezian F; Durozard P; Pelletier J; Audoin B
    Neurol Neuroimmunol Neuroinflamm; 2023 Sep; 10(5):. PubMed ID: 37550074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study.
    Araujo L; Geertsen SS; Amedume A; Higuchi K; van Wingerden J
    Neurol Ther; 2022 Dec; 11(4):1735-1748. PubMed ID: 36152222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
    Freeman L; Kee A; Tian M; Mehta R
    Drugs Real World Outcomes; 2021 Dec; 8(4):497-508. PubMed ID: 34136997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Clinical and Economic Outcomes Among Persons With Multiple Sclerosis Initiating First- Versus Second- or Later-Line Treatment With Ocrelizumab.
    Geiger CK; Sheinson D; To TM; Jones D; Bonine NG
    Neurol Ther; 2023 Oct; 12(5):1709-1728. PubMed ID: 37458897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Qualitative factors shaping MS patients' experiences of infusible disease-modifying drugs: a critical incident technique analysis.
    Larsen JL; Schäfer J; Nielsen HH; Vestergaard Rasmussen P
    BMJ Open; 2020 Aug; 10(8):e037701. PubMed ID: 32819993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of Utilization and Expenditure Across Multiple Sclerosis Disease-Modifying Therapies: A Retrospective Cohort Study Using Claims Data from a Commercially Insured Population in the United States, 2010-2019.
    Zhu W; Tang X; Heyman RA; Cai T; Suh K; Seeger JD; Xia Z
    Neurol Ther; 2022 Sep; 11(3):1147-1165. PubMed ID: 35598225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dimethyl fumarate is associated with lower rates of infection and lower infection-related healthcare costs when compared with ocrelizumab.
    Nicholas JA; Gudesblatt M; Garabedian M; Belviso N; Shen C; Geremakis C; Shankar SL; Mendoza JP; Lewin JB
    Mult Scler Relat Disord; 2022 Jul; 63():103921. PubMed ID: 35700674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health plan utilization and costs of specialty drugs within 4 chronic conditions.
    Gleason PP; Alexander GC; Starner CI; Ritter ST; Van Houten HK; Gunderson BW; Shah ND
    J Manag Care Pharm; 2013 Sep; 19(7):542-8. PubMed ID: 23964615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
    J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis.
    Frisell T; Forsberg L; Nordin N; Kiesel C; Alfredsson L; Askling J; Hillert J; Olsson T; Piehl F
    Mult Scler; 2016 Jan; 22(1):85-93. PubMed ID: 25921036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.